Fusion of metabolic function and morphology: Sequential [ 18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer

Journal of Clinical Oncology

Volumn 25, Issue 23, 2007, Pages 3440-3447

  Du, Yong ^a   Cullum, Ian ^a   Illidge, Tim M ^a   Ell, Peter J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE LESION; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34548161887     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.2854     Document Type: Article

References (40)

1. Juweid ME, Cheson BD: Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507, 2006
2. von Schulthess GK, Steinert HC, Hany TF: Integrated PET/CT: Current applications and future directions. Radiology 238:405-422, 2006
3. Ell PJ: The contribution of PET/CT to improved patient management. Br J Radiol 79:32-36, 2006
4. Fogelman I: Osteoblastic bone metastases in breast cancer: Is not seeing believing? Eur J Nucl Med Mol Imaging 32:1250-1252, 2005
5. Fogelman I, Cook G, Israel O, et al: Positron emission tomography and bone metastases. Semin Nucl Med 35:135-142, 2005
6. Williams HT, Smith S: FDG PET and SPECTof bone metastases in breast cancer. AJR Am J Roentgenol 185:1651-1652, 2005
7. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350:1655-1664, 2004
8. Nielsen OS, Munro AJ, Tannock IF: Bone metastases: Pathophysiology and management policy. J Clin Oncol 9:509-524, 1991
9. Coleman RE: Management of bone metastases. Oncologist 5:463-470, 2000
10. Hortobagyi GN: Progress in the management of bone metastases: One continent at a time? J Clin Oncol 23:3299-3301, 2005
11. Palmedo H, Manka-Waluch A, Albers P, et al: Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21:2869-2875, 2003
12. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785-1791, 1996
13. Hortobagyi GN: Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 29:134-144, 2002 (3 suppl 11)
14. Gainford MC, Dranitsaris G, Clemons M: Systemic treatment of bone metastases from breast cancer: Is it all that it's cracked up to be? J Clin Oncol 23:4802-4803, 2005
15. Hamaoka T, Madewell JE, Podoloff DA, et al: Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942-2953, 2004
16. Langsteger W, Heinisch M, Fogelman I: The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36:73-92, 2006
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Cook GJ, Houston S, Rubens R, et al: Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998
19. Uematsu T, Yuen S, Yukisawa S, et al: Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol 184:1266-1273, 2005
20. Nakai T, Okuyama C, Kubota T, et al: Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 32:1253-1258, 2005
21. Abe K, Sasaki M, Kuwabara Y, et al: Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 19:573-579, 2005
22. An YS, Yoon JK, Lee MH, et al: False negative F-18 FDG PET/CT in nonsmall cell lung cancer bone metastases. Clin Nucl Med 30:203-204, 2005
23. Israel O, Goldberg A, Nachtigal A, et al: FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging 33:1280-1284, 2006
24. Sugawara Y, Zasadny KR, Neuhoff AW, et al: Reevaluation of the standardized uptake value for FDG: Variations with body weight and methods for correction. Radiology 213:521-525, 1999
25. Bland JM, Altman DG: Survival probabilities (the Kaplan-Meier method). BMJ 317:1572, 1998
26. Bland JM, Altman DG: The logrank test. BMJ 328:1073, 2004
27. Shankar LK, Hoffman JM, Bacharach S, et al: Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059-1066, 2006
28. Käkönen SM, Mundy GR: Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97:834-839, 2003 (3 suppl)
29. Hunt NC, Fujikawa Y, Sabokbar A, et al: Cellular mechanisms of bone resorption in breast carcinoma. Br J Cancer 85:78-84, 2001
30. Roodman GD: Biology of osteoclast activation in cancer. J Clin Oncol 19:3562-3571, 2001
31. Mastro AM, Gay CV, Welch DR, et al: Breast cancer cells induce osteoblast apoptosis: A possible contributor to bone degradation. J Cell Biochem 91:265-276, 2004
32. Croucher PI, Shipman CM, Lippitt J, et al: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540, 2001
33. Nakamoto Y, Cohade C, Tatsumi M, et al: CT appearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology 237:627-634, 2005
34. Schmidt GP, Schoenberg SO, Schmid R, et al: Screening for bone metastases: Whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939-949, 2007
35. Metser U, Lerman H, Blank A, et al: Malignant involvement of the spine: Assessment by 18F-FDG PET/CT. J Nucl Med 45:279-284, 2004
36. Stafford SE, Gralow JR, Schubert EK, et al: Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 9:913-921, 2002
37. Specht JM, Tam SL, Kurland BF, et al: Serial 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat [epub ahead of print on February 1, 2007]
38. Miller TR, Wallis JW, Grothe RA Jr: Design and use of PET tomographs: The effect of slice spacing. J Nucl Med 31:1732-1739, 1990
39. Syed R, Bomanji JB, Nagabhushan N, et al: Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer 92:1046-1050, 2005
40. Taira AV, Herfkens RJ, Gambhir SS, et al: Detection of bone metastases: Assessment of integrated FDG PET/CT imaging. Radiology 243:204-211, 2007